The approval for the product was received by company's wholly owned subsidiary firm from the European Medicines Agency, Sun Pharmaceutical Industries said in a filing to BSE.
The company and its subsidiaries continue to file multiple products across multiple countries on an on-going basis, Sun Pharma said while replying to a clarification on a news report sought by the exchange.
"However this is not a material development for the company," it added.
Shares of Sun Pharmaceutical Industries today closed at Rs 649.30 per scrip on BSE, up 4.31 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content